{"paper_id":"6e492e3b-31af-482e-b1b1-859ee0142de8","body_text":"Gynecology, Obstetrics and Perinatology - Gynecology, Obstetrics and Perinatology - 2019 volume 18 issue 2\nThe clinical effectiveness and pathogenetic mechanisms of using human recombinant interferon alpha-2b in combined treatment of patients with external genital endometriosis\nAuthors / Institutions\nE.I.Durneva /\nMaria I. Yarmolinskaya /\nD.I.Sokolov /\nSergey A. Selkov /\nA.V.Selutin /\nThe objective. Assessment of the clinical effectiveness and pathogenetic mechanisms of administration of human recombinant interferon alpha-2b (IFNα-2b) in combined treatment of patients with external genital endometriosis (EGE).\nPatients and methods. We examined 46 patients aged 21 до 43 years with a histologically confirmed diagnosis of EGE (stage I and II according to the R-AFS classification ), among which 21 patients (treatment group) received standard therapy with gonadotropin-releasing hormone agonists (GnRHa) for 6 months in combination with IFNα-2b, and 25 patients (comparison group) – GnRHa monotherapy for 6 months. Also, the control group was singled out (20 women), in whom no gynaecological\npathology was found intraoperatively. Before operative intervention and 6 months after treatment started, the pain syndrome was assessed. The levels of IL-8, IP-10, TNF-α, MCP-1, RANTES were determined in peripheral blood (PB) and peritoneal fluid (PF).\nResults. Patients with EGE had a characteristic increase of PF concentrations of IL-8, TNF-α, MCP-1, RANTES and decreased levels of IP-10. Combined treatment with the use of IFNα-2b demonstrated a more marked decrease of RANTES and increase of MCP-1 in PB, as well as a greater clinical efficacy than in the comparison group.\nConclusion. The impact of IFNα-2b on the cytokine profile as part of combined EGE therapy is indicative of a more intense inhibition of neoangiogenesis and inflammation compared to GnRHa therapy, therefore, its administration is pathogenetically justified.\nKey words: interferon, cytokines, endometriosis.\nFor citation: Durneva E.I., Yarmolinskaya M.I., Sokolov D.I., Sel’kov S.A., Selyutin A.V. The clinical effectiveness and pathogenetic mechanisms of using human recombinant interferon alpha-2b in combined treatment of patients with external genital endometriosis. Vopr. ginekol. akus. perinatol. (Gynecology, Obstetrics and Perinatology). 2019; 18(2): 61–68. (In Russian).\nDOI: 10.20953/1726-1678-2019-2-61-68\nPatients and methods. We examined 46 patients aged 21 до 43 years with a histologically confirmed diagnosis of EGE (stage I and II according to the R-AFS classification ), among which 21 patients (treatment group) received standard therapy with gonadotropin-releasing hormone agonists (GnRHa) for 6 months in combination with IFNα-2b, and 25 patients (comparison group) – GnRHa monotherapy for 6 months. Also, the control group was singled out (20 women), in whom no gynaecological\npathology was found intraoperatively. Before operative intervention and 6 months after treatment started, the pain syndrome was assessed. The levels of IL-8, IP-10, TNF-α, MCP-1, RANTES were determined in peripheral blood (PB) and peritoneal fluid (PF).\nResults. Patients with EGE had a characteristic increase of PF concentrations of IL-8, TNF-α, MCP-1, RANTES and decreased levels of IP-10. Combined treatment with the use of IFNα-2b demonstrated a more marked decrease of RANTES and increase of MCP-1 in PB, as well as a greater clinical efficacy than in the comparison group.\nConclusion. The impact of IFNα-2b on the cytokine profile as part of combined EGE therapy is indicative of a more intense inhibition of neoangiogenesis and inflammation compared to GnRHa therapy, therefore, its administration is pathogenetically justified.\nKey words: interferon, cytokines, endometriosis.\nFor citation: Durneva E.I., Yarmolinskaya M.I., Sokolov D.I., Sel’kov S.A., Selyutin A.V. The clinical effectiveness and pathogenetic mechanisms of using human recombinant interferon alpha-2b in combined treatment of patients with external genital endometriosis. Vopr. ginekol. akus. perinatol. (Gynecology, Obstetrics and Perinatology). 2019; 18(2): 61–68. (In Russian).\nDOI: 10.20953/1726-1678-2019-2-61-68","source_license":"CC0","license_restricted":false}